Abstract
Gemcitabine and 5-fluorouracil are the only two compounds with reproducible activity against advanced pancreatic cancer (APC). We have evaluated a novel combination of gemcitabine and 5-fluorouracil on the clinical benefit response (CBR) end point. Eleven consecutive patients with symptomatic APC were entered in a two-stage phase II trial. Gemcitabine was administered by intravenous (i.v.) bolus injection at the dose of 1000 mg m−2on days 1, 8, 15 and 5-fluorouracil 500 mg m−2was given by continuous i.v. infusion on days 1–5. Treatment was repeated every 28 days. A CBR was achieved in 7/11 patients. The mean time to loss of CBR was 26.5 weeks (range 14–18, median 22). Toxicity was mild and no APC patient experienced WHO grade 3 toxicity. The gemcitabine/5-fluorouracil combination is well tolerated and produces a symptomatic relief in the majority of APC patients. © 2000 Cancer Research Campaign
Keywords: advanced pancreatic cancer, phase II study, gemcitabine, 5-fluorouracil, clinical benefit response
Full Text
The Full Text of this article is available as a PDF (52.2 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Aaronson N. K., Ahmedzai S., Bergman B., Bullinger M., Cull A., Duez N. J., Filiberti A., Flechtner H., Fleishman S. B., de Haes J. C. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365–376. doi: 10.1093/jnci/85.5.365. [DOI] [PubMed] [Google Scholar]
- Burris H. A., 3rd, Moore M. J., Andersen J., Green M. R., Rothenberg M. L., Modiano M. R., Cripps M. C., Portenoy R. K., Storniolo A. M., Tarassoff P. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997 Jun;15(6):2403–2413. doi: 10.1200/JCO.1997.15.6.2403. [DOI] [PubMed] [Google Scholar]
- Carmichael J. Clinical response benefit in patients with advanced pancreatic cancer. Role of gemcitabine. Digestion. 1997;58(6):503–507. doi: 10.1159/000201493. [DOI] [PubMed] [Google Scholar]
- Crown J., Casper E. S., Botet J., Murray P., Kelsen D. P. Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma. J Clin Oncol. 1991 Sep;9(9):1682–1686. doi: 10.1200/JCO.1991.9.9.1682. [DOI] [PubMed] [Google Scholar]
- Noble S., Goa K. L. Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs. 1997 Sep;54(3):447–472. doi: 10.2165/00003495-199754030-00009. [DOI] [PubMed] [Google Scholar]
- Rubin J., Gallagher J. G., Schroeder G., Schutt A. J., Dalton R. J., Kugler J. W., Morton R. F., Mailliard J. A., Burch P. A. Phase II trials of 5-fluorouracil and leucovorin in patients with metastatic gastric or pancreatic carcinoma. Cancer. 1996 Nov 1;78(9):1888–1891. doi: 10.1002/(sici)1097-0142(19961101)78:9<1888::aid-cncr7>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
- Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989 Mar;10(1):1–10. doi: 10.1016/0197-2456(89)90015-9. [DOI] [PubMed] [Google Scholar]
- Stephens C. D. Gemcitabine: a new approach to treating pancreatic cancer. Oncol Nurs Forum. 1998 Jan-Feb;25(1):87–93. [PubMed] [Google Scholar]
- Von Hoff D. D. Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with gemcitabine. San Antonio Drug Development Team. Invest New Drugs. 1996;14(3):265–270. doi: 10.1007/BF00194529. [DOI] [PubMed] [Google Scholar]